SCHEMBL4029705

SCHEMBL4029705

Cn1nnnc1-c1cc(C(=O)NCC(=O)O)ccc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
HIF1A Q16665 2/20 0.45
MAPT P10636 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
SLC22A8 Q8TCC7 1/20 0.45
PTPRC P08575 2/20 0.43
CTSL P07711 1/20 0.43
PTPN13 Q12923 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
TYMS P04818 1/20 0.39
MAPK1 P28482 1/20 0.39
USP5 P45974 2/20 0.37
F2 P00734 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EGLN1 Q9GZT9 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4030744 0.74 KDM4E (0.47) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL15631021 0.71 KDM4E (0.60) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL15630979 0.69 HDAC1 (0.63) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL10062585 0.69 KDM4E (0.60) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL10029217 0.69 CA1 (0.61) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL15610485 0.69 HDAC1 (0.63) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL15631040 0.69 HDAC1 (0.63) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL15942890 0.68 KDM4E (0.55) KDM4EHIF1AMAPTSLC22A6SLC22A8
SCHEMBL20779635 0.67 LMNA (0.40) HIF1ANPSR1RXFP1CA1CA2
SCHEMBL7824602 0.66 NR1H4 (0.62) KDM4EHIF1AMAPTSLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537075-B1 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH AS (DK) 2009-07-01 EP disclosed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP disclosed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C KDM4E 1042/4885HIF1A 374/4885MAPT 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.